ClinicalTrials.gg
CompletedNCT00501059ARRIVEUpdated Oct 26, 2018Results posted

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

A Phase 3 interventional study of Aspirin (Acetylsalicylic acid, BAYE4465) and Placebo in Moderate Risk of CVD, sponsored by Bayer. Completed at 466 sites in 8 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,546
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing aspirin in Stroke — 8 open to participants now, 10 under way, 3 of them phase 3. Aspirin · Stroke.

Enrollment
3rd of 41
12,546 · median 675
Started
2007
with 3 others
Phase 3
11 of 42
2 open now
Registered
7th of 42
by date
Lead sponsor
2 of 42
Bayer

Among the 42 studies testing aspirin in Stroke, this one is the 3rd largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 7th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,067 are open to participants now.

Browse Stroke studies →

Open to participants now

8 of the 42 studies testing aspirin in Stroke are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing aspirin in Stroke, or all of them as a file.
02

Study summary

The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and CV death, in a population with no history of known CVD who are at moderate risk of major CHD events (approximately 10-20% 10 year CHD risk). This corresponds to a patient population mean 10-year CVD risk of approximately 30%. Subjects are treated in a standard care setting and may receive treatment for the underlying risk factors as defined by the treating physician. Outcome events will be adjudicated by an Endpoint Adjudication Committee and the study will be monitored by an independent Data Safety Monitoring Board.

Read the detailed description

Summary of substantial Protocol amendments

Amendment #2 from 09-APR-2008:

  • Systolic blood pressure (SBP) limit of 170 mmHg has been added to the exclusion criteria
  • Exclusion of patients currently taking anticoagulant medication
  • A longer interval between the daily dose of study drug and ibuprofen
  • Revised wording in moderate risk definitions for coronary heart disease (CHD) and cerebrovascular disease (CVD): "To evaluate the clinical effects of a 100 mg/day enteric-coated acetylsalicylic acid versus placebo in the reduction of CVD events in patients at moderate risk of major CHD events (approximately 10 to 20% 10-year CHD risk; approximately 20 to 30% 10-year risk of CVD). This corresponds to a patient population mean 10-year CVD risk of approximately 30%."

Amendment #3 from 02-JAN-2009

  • Increase in the number of allowed risk factors for males, age is no longer a risk factor

Amendment #4 from 02-OCT-2013

  • The primary endpoint is changed to include confirmed UA and TIA.
  • The estimated event rate is changed to 1.5% per year due to new information.
  • Effect size (risk reduction) changed from 14.9% to 17 to 18%.
  • Achieving 60,000 person-years instead of 1488 primary endpoint events
  • Additional treatment and follow-up for a maximum of another 12 months.
  • Change to reduced adverse event and concomitant therapy reporting
03

Conditions studied

  • Moderate Risk of CVD

Browse trials for

Keywords

  • Primary prevention of coronary heart disease
  • Stroke and cardiovascular death
  • Aspirin
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 55 years and above with 2 to 4 risk factors. Male Risk Factors:

    • Elevated cholesterol (Tchol>200 mg/dL or LDL>130 mg/dL; as measured at screening) irrespective of current treatment
    • Current smoking: defined as any cigarette smoking in the past 12 months
    • Low HDL cholesterol (HDL\<40 mg/dL; as measured at screening)
    • Elevated blood pressure (SBP>140 mmHg; as measured at screening)
    • Currently on any medication to treat high blood pressure
    • Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years)
  • Females aged 60 and above with 3 or more risk factors. Female Risk Factors:

    • Elevated cholesterol (Tchol>240 mg/dL or LDL>160 mg/dL; as measured at screening) irrespective of current treatment
    • Current smoking: defined as any cigarette smoking in the past 12 months
    • Low HDL cholesterol (HDL\<40 mg/dL; as measured at screening)
    • Elevated blood pressure (SBP>140 mmHg; as measured at screening)
    • Currently on any medication to treat high blood pressure
    • Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years)
  • An understanding and willingness to comply with trial procedures and has given written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • History of a documented vascular event, such as MI, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant arrhythmias, or congestive heart failure or vascular intervention
  • Patients who are at higher than moderate risk on the basis of their diabetes status, other factors known to the investigator, or the currently used national risk score
  • Known to the study drug, e.g. to acetylsalicylic acid
  • Recent (in the past year) history of gastrointestinal or genitourinary bleeding or other bleeding disorders
  • Active diagnosed and documented reflux esophagitis
  • Patients presenting with any medical condition, or psychiatric or substance abuse disorder, that, in the opinion of the investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study
  • Lactating women or women of
  • Severe liver disease or damage based on the clinical judgment of the investigator
  • Severe renal disease or damage based on the clinical judgement of the investigator
  • A definite indication for acetylsalicylic acid therapy, other antiplatelet drug, or anticoagulant in the opinion of the physician
  • A history of asthma induced by administration of salicylates or substances with a similar action, notably NSAIDS
  • Chronic, frequent (> 5 days/month) use of NSAIDs (including aspirin, or aspirin containing products), COX-2 inhibitors or metamizole
  • Current participation in any other trials involving products within 30 days prior to the Screening Visit
  • Current use of an anticoagulant medication
  • Sitting systolic blood pressure greater than 170 mmHg
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12,546 participants (actual)

Study arms

  • Experimental
    Acetylsalicylic acid (Aspirin, BAYE4465)

    Participants received 1 tablet of enteric-coated acetylsalicylic acid \[100 milligram (mg)\] orally once daily.

    Drug: Aspirin (Acetylsalicylic acid, BAYE4465)

  • Placebo comparator
    Placebo

    Participants received 1 tablets of matching placebo orally once daily.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)

    The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

    Time frame: Until follow-up (approximate 6 years)

Secondary outcomes

  1. Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)

    The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

    Time frame: Until follow-up (approximate 6 years)

  2. Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA

    The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

    Time frame: Until follow-up (approximately 6 years)

  3. Time to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer

    The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

    Time frame: Until follow-up (approximately 6 years)

  4. Incidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer

    Time frame: Until follow-up (approximately 6 years)

  5. Incidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately

    The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. \*all other CV death without fatal MI and fatal stroke

    Time frame: Until follow-up (approximately 6 years)

Other outcomes

  1. Number of Subjects With Adjudicated GI Bleeding by Severity

    Time frame: Until follow-up (approximate 6 years)

  2. Incidence of Composite Outcomes and Non-fatal MI

    Time frame: Until follow-up (approximate 6 years)

  3. Incidence of Composite Outcomes and Individual Outcomes in Per-protocol Population

    \*all other CV death without fatal MI and fatal stroke.

    Time frame: Until follow-up (approximate 6 years)

07

Results

Posted Jan 8, 2018
Limitations and caveats
The reported analyses are limited to endpoint events that met strict criteria. Further blinded review of events is ongoing to identify endpoints based on pragmatic criteria. Interpretations for clinical decision making should await future reporting.

Participant flow

Overall, 15823 subjects were screened. Of these, 3277 subjects were screening failures. The remaining 12546 subjects were randomized to treatment.

Participant flow — Overall Study
MilestoneAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Started62706276
Completed44024384
Not completed18681892
Withdrew: Protocol violation8069
Withdrew: Death140137
Withdrew: Other236239
Withdrew: Missing end-of-study page9192
Withdrew: Clinical endpoint reached110123
Withdrew: Insufficient therapeutic effect45
Withdrew: Consent withdrawn by subject817873
Withdrew: Non-compliant with study treatment2316
Withdrew: Reason not given31
Withdrew: Adverse event129122
Withdrew: Lost to follow-up210198
Withdrew: Not treated2517

Outcome measures

PrimaryTime to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)

The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

Time frame:
Until follow-up (approximate 6 years)
Reported as:
Count of units · Days
Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)
DaysAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Days until 1% subjects had an efficacy event528381
Days until 2% subjects had an efficacy event889796
Days until 3% subjects had an efficacy event12251134
Days until 4% subjects had an efficacy event16301582
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.597
SecondaryTime to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)

The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

Time frame:
Until follow-up (approximate 6 years)
Reported as:
Count of units · Days
Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)
DaysAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Days until 1% subjects had an efficacy event678522
Days until 2% subjects had an efficacy event11671053
Days until 3% subjects had an efficacy event15991501
Days until 4% subjects had an efficacy event19491930
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.6125
SecondaryTime to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA

The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

Time frame:
Until follow-up (approximately 6 years)
Reported as:
Count of units · Days
Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA
DaysAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Days until 1% subjects had non-fatal MI13091085
Days until 2% subjects had non-fatal MINA2121
Days until 1% subjects had total MI12161014
Days until 2% subjects had total MI21281906
Days until 1% subjects had non-fatal stroke15761650
Days until 2% subjects had non-fatal strokeNANA
Days until 1% subjects had total stroke15431627
Days until 2% subjects had total strokeNANA
Days until 1% subjects had cardiovascular deathNANA
Days until 2% subjects had cardiovascular deathNANA
Days until 1% subjects had UANANA
Days until 2% subjects had UANANA
Days until 1% subjects had TIANANA
Days until 2% subjects had TIANANA
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.4505
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.229
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.3947
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.5125
SecondaryTime to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer

The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.

Time frame:
Until follow-up (approximately 6 years)
Reported as:
Count of units · Days
Time to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer
DaysAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Days until 1% subjects had all-cause mortality838938
Days until 2% subjects had all-cause mortality14931460
Days until 3% subjects had all-cause mortality19701963
Days until 4% subjects had all-cause mortalityNANA
Days until 1% subjects had all cancer excl. NMSC374420
Days until 2% subjects had all cancer excl. NMSC849805
Days until 3% subjects had all cancer excl. NMSC11641276
Days until 4% subjects had all cancer excl. NMSC15421751
Days until 1% subjects had colon cancerNANA
Days until 2% subjects had colon cancerNANA
Days until 3% subjects had colon cancerNANA
Days until 4% subjects had colon cancerNANA
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.9544
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.4422
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.611
SecondaryIncidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer
Time frame:
Until follow-up (approximately 6 years)
Reported as:
Number · Percentage of participants
Incidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer
Percentage of participantsAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
all-cause mortality2.552.57
all cancers excluding non-melanoma skin cancer4.023.76
colon cancer0.480.41
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.9459 · Cox proportional hazard: 0.99 · 95% CI 0.80 to 1.24
SecondaryIncidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately

The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. \*all other CV death without fatal MI and fatal stroke

Time frame:
Until follow-up (approximately 6 years)
Reported as:
Number · Percentage of participants
Incidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately
Percentage of participantsAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
MI1.521.78
stroke1.201.07
CV death*0.610.62
UA0.320.32
TIA0.670.72
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.2325 · Cox proportional hazard: 0.85 · 95% CI 0.64 to 1.11
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.5072 · Cox proportional hazard: 1.12 · 95% CI 0.80 to 1.55
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.9010 · Cox proportional hazard: 0.97 · 95% CI 0.62 to 1.52
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.9979 · Cox proportional hazard: 1.00 · 95% CI 0.54 to 1.86
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.7455 · Cox proportional hazard: 0.93 · 95% CI 0.61 to 1.42
Other pre-specifiedNumber of Subjects With Adjudicated GI Bleeding by Severity
Time frame:
Until follow-up (approximate 6 years)
Reported as:
Count of participants · Participants
Number of Subjects With Adjudicated GI Bleeding by Severity
ParticipantsAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
Total6129
Mild4222
Moderate155
Severe42
Other pre-specifiedIncidence of Composite Outcomes and Non-fatal MI
Time frame:
Until follow-up (approximate 6 years)
Reported as:
Number · Percentage of participants
Incidence of Composite Outcomes and Non-fatal MI
Percentage of participantsAcetylsalicylic Acid (Aspirin, BAYE4465)Placebo
MI, stroke, CV death, UA or TIA4.294.48
MI, stroke or CV death3.323.47
non-fatal MI1.401.56
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.6038 · Cox proportional hazard: 0.96 · 95% CI 0.81 to 1.13
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.6190 · Cox proportional hazard: 0.95 · 95% CI 0.79 to 1.15
  • Acetylsalicylic Acid (Aspirin, BAYE4465) vs Placebo · Log Rank · p = 0.4562 · Cox proportional hazard: 0.90 · 95% CI 0.67 to 1.20
Other pre-specifiedIncidence of Composite Outcomes and Individual Outcomes in Per-protocol Population

\*all other CV death without fatal MI and fatal stroke.

Time frame:
Until follow-up (approximate 6 years)
Reported as:
Number · Percentage of participants
Incidence of Composite Outcomes and Individual Outcomes in Per-protocol Population
Percentage of participantsAcetylsalicylic Acid (Aspirin, BAYE4465) Per-protocolPlacebo Per-protocol
MI, stroke, CV death, UA or TIA3.404.19
MI, stroke or CV death2.723.45
MI0.981.84
Non-fatal MI0.841.53
Stroke1.060.95
CV death*0.690.66
UA0.210.28
TIA0.500.49
All-cause mortality2.852.58
Statistical analysis
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.0756 · Cox proportional hazard: 0.81 · 95% CI 0.64 to 1.02
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.0661 · Cox proportional hazard: 0.79 · 95% CI 0.61 to 1.02
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.0014 · Cox proportional hazard: 0.53 · 95% CI 0.36 to 0.79
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.0056 · Cox proportional hazard: 0.55 · 95% CI 0.36 to 0.84
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.6291 · Cox proportional hazard: 1.12 · 95% CI 0.71 to 1.75
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.9161 · Cox proportional hazard: 1.03 · 95% CI 0.60 to 1.77
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.5380 · Cox proportional hazard: 0.75 · 95% CI 0.30 to 1.87
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.9181 · Cox proportional hazard: 1.03 · 95% CI 0.55 to 1.95
  • Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol vs Placebo Per-protocol · Log Rank · p = 0.4796 · Cox proportional hazard: 1.10 · 95% CI 0.84 to 1.45

Adverse events

Collected over Until follow-up (approximately 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1,311/6,276 (20.9%)5,053/6,276 (80.5%)
Acetylsalicylic Acid—1,266/6,270 (20.2%)5,059/6,270 (80.7%)
Most frequent serious events
Showing 10 of 992
Most frequent serious events
EventPlaceboAcetylsalicylic Acid
OsteoarthritisMusculoskeletal and connective tissue disorders103/6276104/6270
Coronary artery diseaseCardiac disorders61/627646/6270
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)44/627659/6270
Acute myocardial infarctionCardiac disorders58/627643/6270
Atrial fibrillationCardiac disorders40/627637/6270
Myocardial infarctionCardiac disorders38/627629/6270
Inguinal herniaGastrointestinal disorders31/627635/6270
Transient ischaemic attackNervous system disorders30/627626/6270
PneumoniaInfections and infestations19/627626/6270
CholelithiasisHepatobiliary disorders17/627624/6270
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboAcetylsalicylic Acid
Back painMusculoskeletal and connective tissue disorders688/6276695/6270
ArthralgiaMusculoskeletal and connective tissue disorders653/6276636/6270
BronchitisInfections and infestations482/6276514/6270
HypertensionVascular disorders514/6276478/6270
CoughRespiratory, thoracic and mediastinal disorders497/6276442/6270
OsteoarthritisMusculoskeletal and connective tissue disorders423/6276468/6270
NasopharyngitisInfections and infestations407/6276421/6270
Lower respiratory tract infectionInfections and infestations420/6276377/6270
DyspepsiaGastrointestinal disorders362/6276374/6270
Upper respiratory tract infectionInfections and infestations371/6276348/6270

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acetylsalicylic Acid (Aspirin, BAYE4465)PlaceboTotal
Mean63.9 ± 7.1063.9 ± 7.0563.9 ± 7.08
Sex: Female, Male
Sex: Female, Male(Participants)Acetylsalicylic Acid (Aspirin, BAYE4465)PlaceboTotal
Female185118573708
Male441944198838
08

Study locations

466 sites
  • Birmingham, Alabama 39294, United States
  • Graysville, Alabama 35073, United States
  • Pell City, Alabama 35125, United States
  • Phoenix, Arizona 85051, United States
  • Scottsdale, Arizona 85260, United States
  • Tucson, Arizona 85712, United States
  • Hot Springs, Arkansas 71913-4457, United States
  • Fremont, California 94536-3702, United States
  • Huntington Park, California 90255, United States
  • Los Angeles, California 90025, United States
  • Rancho Cucamonga, California 91730, United States
  • Rolling Hills Estates, California 90274, United States
  • Helping Hands Clinical Trials
    Santa Ana, California 92704, United States
  • Newark, Delaware 19702, United States
  • Medical Research Trust
    Boynton Beach, Florida 33426, United States
  • Gainesville, Florida 32601, United States
  • Hialeah, Florida 33016, United States
  • Medical Research Centers of South Florida, Inc.
    Hollywood, Florida 33021, United States
  • Office of Dr.Larry Levinson, DO
    Hollywood, Florida 33021, United States
  • Kissimmee, Florida 34741, United States
  • Largo, Florida 33770, United States
  • Marianna, Florida 32446-2120, United States
  • Panama City, Florida 32401, United States
  • Tallahassee Memorial Family
    Quincy, Florida 32351, United States
  • Tampa, Florida 33614, United States
  • Atlanta, Georgia 30318, United States
  • Chicago, Illinois 60628, United States
  • Chicago, Illinois 60631-1958, United States
  • Lockport, Illinois 60491, United States
  • Vernon Hills, Illinois 60061, United States
  • Evansville, Indiana 47713, United States
  • Fort Wayne, Indiana 46804, United States
  • Lebanon, Kentucky 40033, United States
  • Prince Frederick, Maryland 20678, United States
  • Bridgman, Michigan 49106, United States
  • Cadillac, Michigan 49601, United States
  • Interlochen, Michigan 49643-9264, United States
  • Troy, Michigan 48085, United States
  • Port Gibson, Mississippi 39150, United States
  • Florissant, Missouri 63031, United States
  • Broken Bow, Nebraska 68822, United States
  • Omaha, Nebraska 68114, United States
  • Omaha, Nebraska 68116-2004, United States
  • Belvidere, New Jersey 07823, United States
  • Cherry Hill, New Jersey 08084, United States
  • Clifton, New Jersey 07013, United States
  • Hainesport, New Jersey 08036, United States
  • Jersey City, New Jersey 07306, United States
  • Lawrenceville, New Jersey 08648, United States
  • Linden, New Jersey 07036, United States
  • PharmaTrials, Inc.
    Perth Amboy, New Jersey 08861, United States
  • Stratford, New Jersey 08084, United States
  • Burlington, North Carolina 27215, United States
  • Columbus, North Carolina 28722, United States
  • Greensboro, North Carolina 27401, United States
  • Raleigh, North Carolina 27609, United States
  • Carlisle, Ohio 45005-3320, United States
  • Marion, Ohio 43302, United States
  • Montgomery, Ohio 45242, United States
  • Perrysburg, Ohio 43551, United States
  • Doylestown, Pennsylvania 18901, United States
  • Duncansville, Pennsylvania 16635, United States
  • Sellersville, Pennsylvania 18960, United States
  • Taylors, South Carolina 29687, United States
  • Daingerfield, Texas 75638, United States
  • McKinney, Texas 75069, United States
  • Rockwall, Texas 75032, United States
  • San Antonio, Texas 78205-1116, United States
  • San Marcos, Texas 78666, United States
  • Stephenville, Texas 76401, United States
  • Sugar Land, Texas 77478, United States
  • Honaker, Virginia 24260, United States
  • Merit Medical Group, Inc.
    Richlands, Virginia 24641-2067, United States
  • Benningen, Baden-Württemberg 71726, Germany
  • Deggingen, Baden-Württemberg 73326, Germany
  • Dossenheim, Baden-Württemberg 69221, Germany
  • Ettlingen, Baden-Württemberg 78275, Germany
  • Graben-Neudorf, Baden-Württemberg 76676, Germany
  • Heilbronn, Baden-Württemberg 74080, Germany
  • Hockenheim, Baden-Württemberg 68766, Germany
  • Ludwigsburg, Baden-Württemberg 71640, Germany
  • Schwetzingen, Baden-Württemberg 68723, Germany
  • Sinzheim, Baden-Württemberg 76547, Germany
  • Stockach, Baden-Württemberg 78333, Germany
  • Stuttgart, Baden-Württemberg 70378, Germany
  • Trossingen, Baden-Württemberg 78647, Germany
  • Weinheim, Baden-Württemberg 69469, Germany
  • Arzberg, Bayern 95659, Germany
  • Bergrheinfeld, Bayern 97493, Germany
  • Dinkelsbühl, Bayern 91550, Germany
  • Gars, Bayern 83536, Germany
  • Hohenau, Bayern 94545, Germany
  • Künzing, Bayern 94550, Germany
  • München, Bayern 80336, Germany
  • Oberaurach, Bayern 97514, Germany
  • Sand Am Main, Bayern 97522, Germany
  • Schrobenhausen, Bayern 86529, Germany
  • Spalt, Bayern 91174, Germany
  • Strasskirchen, Bayern 94342, Germany
  • Sulzbach-Rosenberg, Bayern 92237, Germany

Showing the first 100 of 466 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26. PubMed 30158069 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Nov 2016, 112 months.

Results were first posted in Jan 2018, 1 year 1 month after primary completion. A results delay was requested in Sep 2017.

Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 112 months is above that.

Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2007
First posted
Jul 13, 2007
StartActual
Jul 5, 2007
Primary completionActual
Nov 15, 2016
CompletionActual
Nov 15, 2016
Results delay requested
Sep 19, 2017
Results first posted
Jan 8, 2018
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00501059
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 13, 2007
Start date
Jul 5, 2007
Primary completion
Nov 15, 2016
Completion
Nov 15, 2016
Results posted
Jan 8, 2018
Last update
Oct 26, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion